US Stock MarketDetailed Quotes
BMEA Biomea Fusion
- 9.570
- +0.800+9.12%
Close Sep 26 16:00 ET
- 9.600
- +0.030+0.31%
Post 20:01 ET
346.53MMarket Cap-2453P/E (TTM)
10.200High8.700Low4.29MVolume8.980Open8.770Pre Close40.59MTurnover19.12%Turnover RatioLossP/E (Static)36.21MShares22.74052wk High3.33P/B214.72MFloat Cap3.61052wk Low--Dividend TTM22.44MShs Float43.690Historical High--Div YieldTTM17.10%Amplitude2.840Historical Low9.459Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Biomea Fusion Stock Forum
trigger sold 1/4 during while market shaky
hope the diabetes study outcome rocket
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Biomea Fusion, Inc. (Nasdaq: BMEA) announced that the FDA has lifted the clinical hold on its ongoing Phase I/II clinical trials of BMF-219, an investigational covalent menin inhibitor, for type 2 and type 1 diabetes(COVALENT-111 and COVALENT-112).
The company's CEO, Thomas Butler, expressed confidence in BMF-219 as a novel, first-in-class agent for diabetes treatment, noting that safety concern...
No comment yet